Hydrophilic poly (ethylene glycol) capped poly (lactic-co-glycolic) acid nanoparticles for subcutaneous delivery of insulin in diabetic rats.
The aim of the present study is to evaluate the effect of insulin loaded poly(ethylene glycol) capped poly(lactic-co-glycolic)acid nanoparticles (ISPPLG NPs) by subcutaneous administration in diabetic rats. A series of biodegradable low molecular weight PLGA [90/10 (PLG2) and 80/20 (PLG4)] copolymers were synthesized by melt polycondensation and their ISPPLG NPs were synthesized by water-oil-water (W/O/W) emulsion solvent evaporation method. The PLGA copolymers and their nanoparticles were characterized. The maximum encapsulation efficiency of ISPPLG4 NPs is 66% and the diameter of the nanoparticles is about 140nm. The in-vivo studies of ISPPLG NPs carried out in diabetic rats by subcutaneous administration show considerable reduction in serum glucose level along with partial restoration of tissue defense systems. Histopathological studies reveal that ISPPLG NPs could restore the damages caused by oxidants during hyperglycaemia. The subcutaneous administration of ISPPLG4 NPs is thus an effective method of reducing hyperglycaemia associated complications.
Department of Veterinary Biochemistry, Madras Veterinary College, Chennai, 600007, Tamilnadu, India.
Saravanan
S
S
Department of Inorganic Chemistry, Guindy Campus, University of Madras, Chennai, 600025, Tamilnadu, India.
Malathi
M
S
Department of Veterinary Biochemistry, Madras Veterinary College, Chennai, 600007, Tamilnadu, India.
Sesh
S
P S L
Department of Veterinary Pharmacology and Toxicology, Madras Veterinary College, Chennai, 600007, Tamilnadu, India.
Selvasubramanian
S
S
Department of Inorganic Chemistry, Guindy Campus, University of Madras, Chennai, 600025, Tamilnadu, India. Electronic address: bala2010@yahoo.com.
Balasubramanian
B
S
Department of Veterinary Biochemistry, Madras Veterinary College, Chennai, 600007, Tamilnadu, India.
Pandiyan
P
V
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002374:Catalase / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D004337:Drug Carriers; D004339:Drug Compounding; D065546:Drug Liberation; D004655:Emulsions; D005979:Glutathione Peroxidase / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism; D057927:Hydrophobic and Hydrophilic Interactions; D007004:Hypoglycemic Agents / Q000378:metabolism / Q000493:pharmacokinetics* / Q000494:pharmacology; D007279:Injections, Subcutaneous; D007328:Insulin / Q000378:metabolism / Q000493:pharmacokinetics* / Q000494:pharmacology; D019344:Lactic Acid / Q000737:chemistry*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism; D010316:Particle Size; D011092:Polyethylene Glycols / Q000737:chemistry*; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin; D013482:Superoxide Dismutase / Q000378:metabolism
D001786:Blood Glucose; D004337:Drug Carriers; D004655:Emulsions; D007004:Hypoglycemic Agents; D007328:Insulin; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D011092:Polyethylene Glycols; D013311:Streptozocin; D006003:Glycogen; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase
Insulin; Nanoparticles; Poly(ethylene glycol); Poly(lactic-co-glycolic)acid; Subcutaneous administration